New York University (NYU) Langone Annual Seminar In Advanced Rheumatology is organized by New York University (NYU) School of Medicine and will be held during Mar 15 - 17, 2018 at NYU Langone Medical Center, New york city, New York, United States of America.
The target audience for this medical event is rheumatologists and trainees in the rheumatic diseases, as well as orthopedists, internists and other physicians with a special interest in rheumatology. This CME Conference has been approved for a maximum of 21.75 AMA PRA Category 1 Credits.
Conference Description :
The annual NYU Langone Health Seminar in Advanced Rheumatology is a two and one-half day conference that will review and address those areas where recent, solid knowledge in the treatment of rheumatic diseases is available, focusing particularly on the state-of-the-art in rheumatology, at the leading edge between new clinical knowledge and its translation into practice. Rheumatology is a fast-moving field in which new discoveries are continually being made, and new treatment modalities developed. Because the basic and clinical scientific underpinnings of rheumatologic practice frequently and directly come to impact therapy
This course will also explore those areas of new science that are likely to prove important to the near-future management of patients with rheumatic disease. Lectures and Year-In-Review updates will provide participants with the latest information in arthritis, lupus and other rheumatologic conditions; panel discussions and optional Meet-the-Professor sessions will allow participants to raise questions and participate in dialogue with the course instructors and clinical experts.
Conference Objectives are :
After participating in this activity, clinicians should be able to:
• Recognize the clinical benefits, and manage risks of protein based biologic therapies for treatment of rheumatoid arthritis, psoriasis and psoriatic arthritis
• Develop strategies to determine when to introduce small-molecule signal transduction inhibitors into treatment
• Recognize the presence of co-morbidities associated with rheumatic diseases and account for these in treatment
• Evaluate new and future treatment approaches for lupus management
• Consider the roles of specific immune cells, genetics and cytokines in the pathogenesis of lupus, and the potential to exploit these factors as therapeutic targets
• Describe the mechanisms of vascular disease, fibrosis and organ system dysfunction in scleroderma and inflammatory vasculitis, and discuss the current treatments for vascular, kidney and pulmonary disease
• Recognize the clinical and biological differences between the various inflammatory myopathies, and consider possible management for inclusion body myositis in particular